Prime Medicine Inc. is a biotechnology company dedicated to developing one-time curative genetic therapies using its proprietary Prime Editing platform. This versatile, precise, and efficient gene editing technology enables targeted modifications at specific genomic sites without inducing double-strand DNA breaks, potentially offering improved tolerability across various cell types. The company advances a diversified pipeline focused on liver, lung, hematology, immunology, and oncology indications, including programs for Wilson's Disease (PM577), Alpha-1 Antitrypsin Deficiency (PM647), cystic fibrosis, p47phox chronic granulomatous disease (PM359), and Prime Edited CAR-T products developed in partnership with Bristol Myers Squibb. Prime Medicine Inc. employs innovative delivery methods such as liver-targeted lipid nanoparticles to support in vivo applications and prioritizes diseases with established biology and regulatory pathways. Incorporated in Delaware and headquartered in Cambridge, Massachusetts, the company operates at the forefront of gene editing to address rare genetic disorders and beyond.